Caricamento...
Outcomes after progression of disease with anti-PD-1/PDL1 therapy for advanced melanoma
BACKGROUND: Over half of patients treated with antibodies blocking programmed death-1 receptor (anti-PD-1) for melanoma experience disease progression. We aimed to identify prognostic factors and outcomes in patients with metastatic melanoma that progressed on anti-PD-1 therapy. METHODS: We evaluate...
Salvato in:
| Pubblicato in: | Cancer |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7695037/ https://ncbi.nlm.nih.gov/pubmed/32463489 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32984 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|